Statistical Learning As a Novel Intervention for Cortical Blindness
Launched by UNIVERSITY OF ROCHESTER · Aug 27, 2024
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Cortically Blind participants
- Inclusion criteria:
- • Between 21 and 75 years of age
- • Residents of the United States or Canada
- • Have successfully completed previous enrollment in Dr. Huxlin study (IRB #5966 or #75)
- • Exhibit unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 75 years (verified by MRI and/or CT scans)
- • Reliable visual field defects in both eyes (homonymous defects) as measured by Humphrey visual fields. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.
- • Able to fixate on visual targets reliably for 1000ms within 1-deg of visual angle.
- • Willing, able, and competent to provide their own informed consent
- • Normal cognitive abilities and be able to understand written and oral instructions in English
- Exclusion criteria:
- • Past or present ocular disease interfering with visual acuity
- • Best corrected visual acuity (BCVA) worse than 20/40 in either eye
- • Sustained documented or suspected damage to the dorsal Lateral Geniculate Nucleus
- • Presence of diffuse whole brain degenerative processes
- • History of traumatic brain injury
- • Any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures
- • Documented history of drug/alcohol abuse
- • Currently taking neuroactive medications which would impact training, as determined by PI
- • Cognitive or seizure disorders
- • One-sided attentional neglect
- • Those who lack the competence or are otherwise unable to perform the visual training exercises as directed.
- • Control participants
- Inclusion criteria:
- • Between 21 and 75 years of age
- • No history of neurological disorder.
- • Competent and responsible, as determined by the screening interview
- Exclusion criteria:
- • Any damage to the visual system
- • Those who are suffering from an active disease process involving their nervous system.
- • Presence of cognitive or seizure disorders
- • Best corrected visual acuity worse than 20/40 in either eye
- • Presence of visual field loss from ocular disease or disorder
About University Of Rochester
The University of Rochester is a leading academic institution dedicated to advancing medical research and improving patient care through innovative clinical trials. Renowned for its commitment to excellence in education, research, and clinical practice, the university fosters a collaborative environment that integrates cutting-edge scientific inquiry with practical applications in healthcare. With a focus on diverse therapeutic areas, the University of Rochester aims to enhance treatment options and outcomes for patients while contributing to the broader scientific community through rigorous study design and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported